Portfolio
8
companies
CHARM Therapeutics
Discovering small molecule therapeutics through proprietary 3D deep-learning protein-ligand technology.
Genomics
Genomics builds precision healthcare tools using large-scale genetic information to prevent common diseases and cancers.
OTA Insight
OTA Insight provides cloud-based business intelligence and analytics for the hospitality industry.
Peptone
Peptone builds atomic-level protein analysis technology for drug discovery.
Proximie
Proximie provides a digital health platform connecting operating rooms globally.
Shift Bioscience
Shift Bioscience uses generative artificial intelligence models to understand how gene activation can reverse the aging process.
Muz Mansuri
Venture Partner
Nihal Sinha
Nihal is a partner at F-Prime Capital and holds board positions at several therapeutics companies. He was previously part of the founding team at Orchard Therapeutics.
LinkedIn
Alex Pasteur
Partner
Alex serves as a partner at F-Prime Capital and holds non-executive director roles across several healthcare and life sciences companies.
LinkedInBGF and Tencent join existing shareholders to support the biotechnology company in advancing its drug development programmes.
"We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support."
The seed round was led by BGF with participation from F-Prime Capital, Kindred Capital, and Jonathan Milner.
"Our technology is addressing the current limitations of cellular reprogramming for treatment of age-related illnesses, "
The funding round was led by F-Prime Capital and Foresight Partners to support risk estimation technology and workforce expansion.
"Our vision is that in 10 to 15 years, genetic information will be ubiquitous in healthcare systems"
The financing round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
"We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies. TCR therapeutics are very much at the dawn of their potential. We intend to replicate the success of therapeutic antibodies but build on this in a new dimension, by using the targeting domains of TCR receptors to take advantage of their much greater specificity for cancer cells compared to normal cells. The same logic can be used to target immunosuppressive biologics to tissues impacted by autoimmune disorders."
The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
